ArticleNature communications2016
Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 173 citations in OpenAlex.
- Glycolysis-driven cancer-associated fibroblasts shape T-Cell exclusion via the CXCL16-CXCR6 Axis: a metabolic-chemokine mechanism in tumor immunity.Journal of translational medicine · 2026Review
- Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026Review
- Review
- Cancer-Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The chemokine network in triple-negative breast cancer: its role in immune microenvironment regulation, and prospects for targeted therapy.Frontiers in immunology · 2026Review
- Characterization of cancer-associated fibroblast populations that promote tertiary lymphoid structure formation in murine melanoma tumors.Frontiers in immunology · 2026Article
- Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer.Biomaterials research · 2026Article
- Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases: a narrative review.Frontiers in immunology · 2026Review
- Epidermal Interferon-κ Drives Cutaneous Lupus-Like Lesions, Photosensitivity, and Systemic Autoimmunity In Vivo.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Collagen dynamics in the breast cancer tumor microenvironment and therapeutic perspectives.Discover oncology · 2025Review
- Crosstalk between heterogeneous cancer-associated fibroblast subpopulations and the immune system in breast cancer: key players and promising therapeutic targets.Journal of experimental & clinical cancer research : CR · 2025Review
- The Role of Tumor Microenvironment in Triple-Negative Breast Cancer and Its Therapeutic Targeting.Cells · 2025Review
- Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments.Signal transduction and targeted therapy · 2025Review
- scCOSMIX: A Mixed-Effects Framework for Differential Coexpression and Transcriptional Interactions Modeling in Single-Cell RNA-Seq.Statistics in medicine · 2025Article
- Extracellular vesicle-hitchhiking nanoliposomes for cancer-associated fibroblast phenotype modulation impede metastasis progression.Science advances · 2025Article
- Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.MedComm · 2025Review
- Altered immune signatures in breast cancer lymph nodes with metastases revealed by spatial proteome analyses.Journal of translational medicine · 2025Article
- Predicting Prognosis and Immunotherapy Response in Glioblastoma (GBM) With a 5-Gene CAF-Risk Signature.Cancer reports (Hoboken, N.J.) · 2025Article
- Cancer associated fibroblasts in cancer development and therapy.Journal of hematology & oncology · 2025Review
- Tumor Microenvironment Dynamics of Triple-Negative Breast Cancer Under Radiation Therapy.International journal of molecular sciences · 2025Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Roni AllaouiDepartment of Translational Medicine, Cancer Immunology, Lund University, Malmö 205 02, Sweden.
Caroline BergenfelzDepartment of Translational Medicine, Cancer Immunology, Lund University, Malmö 205 02, Sweden.
Sofie MohlinDepartment of Laboratory Medicine, Translational Cancer Research, Lund University, Lund 223 63, Sweden.
Catharina HagerlingDepartment of Translational Medicine, Cancer Immunology, Lund University, Malmö 205 02, Sweden.
Kiarash SalariDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143-0452, USA.
Zena WerbDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143-0452, USA.
Robin L AndersonSir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne 8006, Australia.
Stephen P EthierDepartment of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Karin JirströmDepartment of Clinical Sciences Lund, Oncology and Pathology, Lund University, Lund 221 85, Sweden.
Sven PåhlmanDepartment of Laboratory Medicine, Translational Cancer Research, Lund University, Lund 223 63, Sweden.
Daniel BexellDepartment of Laboratory Medicine, Translational Cancer Research, Lund University, Lund 223 63, Sweden.ORCID 0000-0001-9426-9550
Balázs TahinDepartment of Translational Medicine, Clinical Pathology, Skånes Universitetssjukhus, Malmö 205 02, Sweden.
Martin E JohanssonDepartment of Translational Medicine, Cancer Immunology, Lund University, Malmö 205 02, Sweden.
Christer LarssonDepartment of Laboratory Medicine, Translational Cancer Research, Lund University, Lund 223 63, Sweden.
Karin LeanderssonDepartment of Translational Medicine, Cancer Immunology, Lund University, Malmö 205 02, Sweden.ORCID 0000-0001-8254-3137
Lund University · SEUniversity of California, San Francisco · USMedical University of South Carolina · USSkåne University Hospital · SEThe University of Melbourne · AU
Funding
Integrative approach to heterogeneity in breast cancer metastasisU01CA199315 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI, SPELLMAN, PAUL T. · 2016 to 2020
$3.2M(PQC4) Fate of cells disseminating from human breast cancer xenograftsR01CA180039 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2013 to 2016
$1.3MNCI NIH HHS R01 CA180039NCI NIH HHS U01 CA199315
Abstract
Triple-negative (TN) breast cancers (ER
Indexed as
AnimalsCancer-Associated FibroblastsCell Line, TumorCell ProliferationCell SurvivalChemokine CXCL16Chemotactic FactorsCoculture TechniquesCollagenFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunosuppression TherapyMice, NudeMonocytesChemokine CXCL16Chemotactic FactorsCollagenCXCL16 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.